Login to Your Account

Cytochroma Flush With Cash for Kidney Disease Trials

By Catherine Hollingsworth

Thursday, July 31, 2008
Cytochroma hopes to advance its three lead products for kidney disease patients, with an infusion of cash from the closing of a C$45 million (US$44 million) Series C financing and C$105 million licensing deal with Japanese drugmaker Mitsubishi Tanabe Pharma Corp. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription